Clinical trials
Phase 2 Breast Neoplasms trials in Brazil
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 7 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 3 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 34 |
| Unknown status | 7 |
| Recruiting | 6 |
| Terminated | 6 |
| Active, not recruiting | 5 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 12 |
| Novartis Pharmaceuticals | 7 |
| Instituto do Cancer do Estado de São Paulo | 5 |
| AstraZeneca | 4 |
| Eli Lilly and Company | 3 |
| Instituto Nacional de Cancer, Brazil | 3 |
| Pfizer | 3 |
| Faculdade de Medicina do ABC | 2 |
| Latin American Cooperative Oncology Group | 2 |
| AC Camargo Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 58 |
| Neoplasms | 6 |
| Breast Diseases | 2 |
| Fatigue | 2 |
| Head and Neck Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
| Neoplasms by Site | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Biliary Tract Neoplasms | 1 |
| Cancer Pain | 1 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.